JPRN-jRCT1080222617未知2 期
A phase II randomized study comparing the efficacy and safety of mFOLFOX6 + panitumumab combination therapy and 5-FU/LV + panitumumab combination therapy in the patients with chemotherapy-naive unresectable advanced recurrent colorectal carcinoma of KRAS wild-type after 6 cycles of combination therapy with mFOLFOX6 + panitumumab
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 164 人开始时间: 2014年9月30日最近更新:
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 164
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Inclusion criteria for enrollment:
- •(1) Patients with unresectable adenocarcinoma originating in the large intestine (excluding carcinoma of the appendix and anal canal cancer)
- •(2) Patients with measurable lesion(s) according to the RECIST ver. 1.1
- •(3) Patients who have not received chemotherapy for colorectal cancer. Patients who experience relapse more than 6 months after the final dose of perioperative adjuvant chemotherapy with fluoropyrimidine agents may be enrolled.
- •(4) Aged>= 20 years at the time of informed consent
- •(5) Patients classified as KRAS wild-type. However, the criteria will be changed to all patients who are verified to be of KRAS and NRAS wild-type when the KRAS and NRAS tests come to be covered by National Health Insurance, and the tests become feasible at medical institutions.
- •(6) Patients who satisfy the following criteria for the major organ function in tests performed within 14 days prior to enrollment
- •1) Neutrophil count >= 1.5 x 103/microL
- •2) White blood cell count >= 3.0 x 103/microL
- •3) Platelet count >= 10.0 x 104/microL
- •4) Hemoglobin >= 9.0 g/dL
- •5) Total bilirubin >= 2.0 mg/dL
- •6) AST >= 100 U/L (<= 200 U/L if liver metastases are present)
- •7) ALT >= 100 U/L (<= 200 U/L if liver metastases are present)
- •8) Serum creatinine <= 1.5 mg/dL
- •(7) Patients who are assessed at Eastern Cooperative Oncology Group (ECOG) performance status (P.S.) of 0 or 1
- •(8) Life expectancy of >= 6 months after enrollment
- •(9) Patients who have given written consent to take part in the study after detailed explanation of the study prior to enrollment
- •Inclusion criteria for randomization:
- •(1) Patients who have received 6 cycles of mFOLFOX6 + panitumumab combination therapy
- •(2) Patients who are assessed at ECOG P.S. of 0-1 in the 6th cycle.
- •(3) Patients for whom PD or not evaluable has been denied on the RECIST based on imaging tests conducted after the day of administration in the 6th cycle within 14 days (2 weeks).
排除标准
- •Exclusion criteria for enrollment:
- •(1) Radiotherapy received for a measurable lesion
- •(2) Radiotherapy received within 28 days (4 weeks) prior to enrollment for a lesion other than measurable lesions
- •(3) Known brain metastasis or strongly suspected of brain metastasis
- •(4) Synchronous cancers or metachronous cancers with a disease-free period of <- 5 years (excluding colorectal cancer) excluding mucosal cancers cured or be possibly cured by regional resection (esophageal, stomach, and cervical cancer, non-melanoma skin cancer, bladder cancer, etc.).
- •(5) Body cavity fluid that requires treatment (pleural effusion, ascites, pericardial effusion, etc.)
- •(6) Patients who do not want to use contraception to prevent pregnancy, and women who are pregnant or breast-feeding, or test positive for pregnancy
- •(7) Active hemorrhage requiring blood transfusion
- •(8) Disease requiring systemic steroids for treatment (excluding topical steroids)
- •(9) Intestinal resection and colostomy within 14 days (2 weeks) prior to enrollment
- •(10) History or obvious and extensive computerized tomography findings of interstitial pulmonary disease (interstitial pneumonia, pulmonary fibrosis, etc.)
- •(11) Serious drug hypersensitivity
- •(12) Local or systemic active infection requiring treatment, or fever indicating infection
- •(13) Intestinal paralysis, gastrointestinal obstruction, or uncontrollable diarrhea (incapacitating symptoms despite adequate treatment)
- •(14) Active hepatitis B and/or active hepatitis C
- •(15) Known human immunodeficiency virus infection
- •(16) Other patients judged by the investigator or subinvestigator to be ineligible for enrollment in the study
- •Exclusion criteria for randomization:
- •(1) Patients in whom interstitial pneumonia has been newly diagnosed during the period from registration to randomization
- •(2) Patients who have received radiotherapy during the period from registration to randomization
- •(3) Other patients judged by the investigator or subinvestigator to be ineligible for enrollment in the study
研究者
相似试验
已完成
2 期
Randomized phase II trial evaluating the efficacy and safety of standard care +/- continuous gefitinib treatment beyond progression in patients with advanced NSCLC after 1st line treatment with gefitinib(TORG1019)EGFR positive non-sqamous non-small cell lung cancerJPRN-UMIN000013316Thoracic Oncology Research Group70
进行中（未招募）
1 期
Randomized phase II trial evaluating the efficacy of FOLFOX alone, FOLFOX plus bevacizumab and FOLFOX plus panitumumab as perioperative treatment in patients with resectable liver metastases from wild type KRAS and NRAS colorectal cancerEUCTR2010-019238-29-BEEuropean Organisation for Research and Treatment of Cancer44
进行中（未招募）
1 期
Randomized phase II trial evaluating the efficacy of FOLFOX alone, FOLFOX plus bevacizumab and FOLFOX plus panitumumab as perioperative treatment in patients with resectable liver metastases from wild type KRAS and NRAS colorectal cancerEUCTR2010-019238-29-NLEuropean Organisation for Research and Treatment of Cancer44
进行中（未招募）
1 期
Randomized phase II trial evaluating the efficacy of FOLFOX alone, FOLFOX plus bevacizumab and FOLFOX plus panitumumab as perioperative treatment in patients with resectable liver metastases from wild type KRAS and NRAS colorectal cancerResectable liver metastases from wild type KRAS and NRAS colorectal cancer.MedDRA version: 17.0 Level: PT Classification code 10052358 Term: Colorectal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0 Level: LLT Classification code 10024700 Term: Liver metastases System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019238-29-ATEuropean Organisation for Research and Treatment of Cancer44
已完成
4 期
To determine the efficacy and safety of Inj Diclofenac 75mg/ml given intradeltoid with Injection Diclofenac 75mg/3ml given intragluteal in the management of postoperative pain in obese patients.CTRI/2009/091/000108Troikaa Pharmaceuticals Limited200